

David Langleben

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5503984/publications.pdf>

Version: 2024-02-01

83
papers

15,101
citations

117625

34
h-index

74163

75
g-index

84
all docs

84
docs citations

84
times ranked

8172
citing authors

#	ARTICLE	IF	CITATIONS
1	A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 1996, 334, 296-301.	27.0	2,529
2	Updated Clinical Classification of Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, S43-S54.	2.8	1,919
3	Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 1993, 328, 1732-1739.	27.0	1,698
4	Clinical classification of pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 43, S5-S12.	2.8	1,542
5	Definitions and Diagnosis of Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D42-D50.	2.8	1,467
6	Riociguat for the Treatment of Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2013, 369, 330-340.	27.0	1,120
7	Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease. <i>Annals of Internal Medicine</i> , 2000, 132, 425.	3.9	905
8	Sitaxsentan Therapy for Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 169, 441-447.	5.6	674
9	Treatment of Pulmonary Arterial Hypertension With the Selective Endothelin-A Receptor Antagonist Sitaxsentan. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2049-2056.	2.8	462
10	Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. <i>European Respiratory Journal</i> , 2019, 53, 1801900.	6.7	315
11	Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). <i>European Respiratory Journal</i> , 2015, 45, 1303-1313.	6.7	174
12	Pulmonary Capillary Endothelium-Bound Angiotensin-Converting Enzyme Activity in Acute Lung Injury. <i>Circulation</i> , 2000, 102, 2011-2018.	1.6	153
13	Short-term Pulmonary Vasodilation With L-Arginine in Pulmonary Hypertension. <i>Circulation</i> , 1995, 92, 1539-1545.	1.6	149
14	Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension. <i>Circulation Research</i> , 2015, 117, 645-654.	4.5	120
15	Familial Pulmonary Capillary Hemangiomas Resulting in Primary Pulmonary Hypertension. <i>Annals of Internal Medicine</i> , 1988, 109, 106.	3.9	117
16	RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. <i>European Respiratory Journal</i> , 2017, 50, 1602425.	6.7	113
17	Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. <i>Lancet Respiratory Medicine</i> , 2016, 4, 361-371.	10.7	97
18	Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 573-584.	10.7	85

#	ARTICLE	IF	CITATIONS
19	Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1345-1354.	5.6	82
20	Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. <i>Chest</i> , 2017, 151, 468-480.	0.8	79
21	Temporal trends and drug exposures in pulmonary hypertension: An American experience. <i>American Heart Journal</i> , 2006, 152, 521-526.	2.7	78
22	Continuous Infusion of Epoprostenol Improves the Net Balance Between Pulmonary Endothelin-1 Clearance and Release in Primary Pulmonary Hypertension. <i>Circulation</i> , 1999, 99, 3266-3271.	1.6	70
23	Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. <i>American Heart Journal</i> , 2002, 143, 4A-10A.	2.7	68
24	Pulmonary Capillary Endothelium-Bound Angiotensin-Converting Enzyme Activity in Humans. <i>Circulation</i> , 1999, 99, 1593-1599.	1.6	62
25	EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. <i>American Heart Journal</i> , 2014, 167, 210-217.	2.7	59
26	Sustained Symptomatic, Functional, and Hemodynamic Benefit With the Selective Endothelin-A Receptor Antagonist, Sitaxsentan, in Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2004, 126, 1377-1381.	0.8	58
27	Etiology-Specific Endothelin-1 Clearance in Human Precapillary Pulmonary Hypertension. <i>Chest</i> , 2006, 129, 689-695.	0.8	55
28	STRIDE 1: Effects of the Selective ETA Receptor Antagonist, Sitaxsentan Sodium, in a Patient Population with Pulmonary Arterial Hypertension that meets Traditional Inclusion Criteria of Previous Pulmonary Arterial Hypertension Trials. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, S80-S84.	1.9	54
29	Combination Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1520-1530.	1.7	50
30	Leaflet Area as a Determinant of Tricuspid Regurgitation Severity in Patients With Pulmonary Hypertension. <i>Circulation: Cardiovascular Imaging</i> , 2015, 8, .	2.6	45
31	Pulmonary capillary endothelial dysfunction in early systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2001, 44, 902-911.	6.7	43
32	Bone morphogenic protein-9 stimulates endothelin-1 release from human pulmonary microvascular endothelial cells. <i>Microvascular Research</i> , 2010, 80, 349-354.	2.5	42
33	Pulmonary capillary endothelial metabolic dysfunction: Severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension. <i>Arthritis and Rheumatism</i> , 2008, 58, 1156-1164.	6.7	40
34	Endothelin Receptor Antagonists in the Treatment of Pulmonary Arterial Hypertension. <i>Clinics in Chest Medicine</i> , 2007, 28, 117-125.	2.1	36
35	REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 513-519.	0.6	29
36	Canadian Cardiovascular Society/Canadian Thoracic Society Position Statement on Pulmonary Hypertension. <i>Canadian Journal of Cardiology</i> , 2020, 36, 977-992.	1.7	29

#	ARTICLE	IF	CITATIONS
37	Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 716-721.	0.6	28
38	Prevalence and Impact of Coronary Artery Disease in Patients With Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2011, 108, 460-464.	1.6	26
39	Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. <i>Chest</i> , 2020, 157, 955-965.	0.8	26
40	Clinical Challenges in Pulmonary Hypertension. <i>Chest</i> , 2005, 128, 622S-628S.	0.8	23
41	ALK2 and BMP2 knockdown and endothelin-1 production by pulmonary microvascular endothelial cells. <i>Microvascular Research</i> , 2013, 85, 46-53.	2.5	23
42	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , 2021, 178, 106220.	2.9	23
43	Effects of bone morphogenic proteins and transforming growth factor-beta on In-vitro production of endothelin-1 by human pulmonary microvascular endothelial cells. <i>Vascular Pharmacology</i> , 2009, 50, 45-50.	2.1	22
44	Pulmonary Arterial Hypertension in the Elderly-Clinical Characteristics and Long-Term Survival. <i>Lung</i> , 2012, 190, 645-649.	3.3	22
45	Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 509-519.	0.6	22
46	Acute Vasodilator Responsiveness and Microvascular Recruitment in Idiopathic Pulmonary Arterial Hypertension. <i>Annals of Internal Medicine</i> , 2015, 162, 154-156.	3.9	20
47	Usefulness of Right Ventricular Dysfunction to Predict New-Onset Atrial Fibrillation Following Coronary Artery Bypass Grafting. <i>American Journal of Cardiology</i> , 2014, 113, 913-918.	1.6	18
48	Effects of vascular endothelial growth factor on endothelin-1 production by human lung microvascular endothelial cells in vitro. <i>Life Sciences</i> , 2014, 118, 191-194.	4.3	18
49	Riociguat: Clinical research and evolving role in therapy. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2645-2662.	2.4	18
50	Pulmonary Capillary Hemangiomas. <i>Chest</i> , 2014, 145, 197-199.	0.8	16
51	The Use of Antidepressants and the Risk of Idiopathic Pulmonary Arterial Hypertension. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1633-1639.	1.7	15
52	Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors. <i>Respiratory Medicine</i> , 2017, 122, S18-S22.	2.9	15
53	Cardiac Catheterization in Pulmonary Arterial Hypertension: An Updated Guide to Proper Use. <i>Advances in Pulmonary Hypertension</i> , 2005, 4, 15-25.	0.1	14
54	Step climbing capacity in patients with pulmonary hypertension. <i>Clinical Research in Cardiology</i> , 2013, 102, 51-61.	3.3	13

#	ARTICLE	IF	CITATIONS
55	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , 2021, 177, 106241.	2.9	13
56	Molecular imaging of the human pulmonary vascular endothelium in pulmonary hypertension: a phase II safety and proof of principle trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1136-1144.	6.4	11
57	Pulmonary capillary surface area in supine exercising humans: demonstration of vascular recruitment. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2019, 317, L361-L368.	2.9	11
58	Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the Phase III PATENT-1 study. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 338-347.	0.6	10
59	Hemodynamic Stability After Transitioning Between Endothelin Receptor Antagonists in Patients With Pulmonary Arterial Hypertension. <i>Canadian Journal of Cardiology</i> , 2013, 29, 672-677.	1.7	9
60	Pregnancy as a Possible Trigger for Heritable Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2016, 6, 381-383.	1.7	9
61	Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1172-1180.	0.6	9
62	Canadian Cardiovascular Society and Canadian Thoracic Society Position Statement on Pulmonary Arterial Hypertension. <i>Canadian Respiratory Journal</i> , 2005, 12, 303-315.	1.6	5
63	Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE. <i>International Journal of Cardiology</i> , 2020, 317, 188-192.	1.7	5
64	The Role of Thyroid Disorders, Obesity, Diabetes Mellitus and Estrogen Exposure as Potential Modifiers for Pulmonary Hypertension. <i>Journal of Clinical Medicine</i> , 2022, 11, 921.	2.4	5
65	Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies). <i>Pulmonary Circulation</i> , 2020, 10, 1-10.	1.7	4
66	Knockdown of bone morphogenetic protein type II receptor leads to decreased aquaporin 1 expression and function in human pulmonary microvascular endothelial cells. <i>Canadian Journal of Physiology and Pharmacology</i> , 2020, 98, 834-839.	1.4	4
67	Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study. <i>Pulmonary Circulation</i> , 2020, 10, 1-8.	1.7	4
68	Canadian Cardiovascular Society and Canadian Thoracic Society position statement on pulmonary arterial hypertension. <i>Canadian Journal of Cardiology</i> , 2005, 21, 909-14.	1.7	4
69	Evaluation of the Microstat [®] , a sublingual PCO ₂ monitor in ambulatory patients. <i>Journal of Clinical Monitoring and Computing</i> , 2016, 30, 77-80.	1.6	3
70	Vasodilator responsiveness in idiopathic pulmonary arterial hypertension: identifying a distinct phenotype with distinct physiology and distinct prognosis. <i>Pulmonary Circulation</i> , 2017, 7, 588-597.	1.7	3
71	Impact of saline loading at cardiac catheterization on the classification and management of patients evaluated for pulmonary hypertension. <i>International Journal of Cardiology</i> , 2020, 306, 181-186.	1.7	3
72	Interspecies Variation in the Cellular Phase of Blood Fibrinolytic Activity. <i>Experimental Biology and Medicine</i> , 1991, 196, 270-272.	2.4	2

#	ARTICLE	IF	CITATIONS
73	Selexipag Therapy for Raynaud Phenomenon-induced Severe Digital Ischemia in Intravenous Epoprostenol Responders With Connective Tissue Disease. <i>Journal of Rheumatology</i> , 2021, 48, 616-617.	2.0	2
74	Pulmonary capillary recruitment and distention in mammalian lungs: species similarities.. <i>European Respiratory Review</i> , 2022, 31, .	7.1	2
75	Pulmonary capillary recruitment in exercise and pulmonary hypertension. <i>European Respiratory Journal</i> , 2018, 51, 1702559.	6.7	1
76	Decreased bone morphogenetic protein type II receptor and BMP-related signalling moleculesâ€™ expression in aquaporin 1-silenced human pulmonary microvascular endothelial cells. <i>Hellenic Journal of Cardiology</i> , 2021, 62, 84-86.	1.0	1
77	Metabolic and Clearance Function at the Pulmonary Microvascular Endothelial Surface in Pulmonary Hypertension. , 2011, , 105-115.		1
78	Systemic Sclerosis and Early-Onset Pulmonary Hypertension. <i>Chest</i> , 2010, 138, 238-239.	0.8	0
79	From the Echo Bed to the Pulmonary Vascular Bed. <i>Chest</i> , 2014, 146, 876-878.	0.8	0
80	Right ventricular STâ€™elevation myocardial infarction as a cause of death in idiopathic pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2017, 7, 555-558.	1.7	0
81	Near-Term Novel Therapies for PAH. <i>Advances in Pulmonary Hypertension</i> , 2009, 8, 17-20.	0.1	0
82	What is the Current State of Stem Cell Research in PAH?. <i>Advances in Pulmonary Hypertension</i> , 2010, 9, 145-145.	0.1	0
83	Endothelin and Its Blockade in Pulmonary Arterial Hypertension. , 2008, , 283-303.		0